Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Qing-ming Yang"'
Autor:
Kai-chao Feng, Ye-lei Guo, Yang Liu, Han-ren Dai, Yao Wang, Hai-yan Lv, Jian-hua Huang, Qing-ming Yang, Wei-dong Han
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-11 (2017)
Abstract Background Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality, and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell (CART) im
Externí odkaz:
https://doaj.org/article/7750ff5736d8430c9b9d3276e7b70e00
Autor:
Yao Wang, Meixia Chen, Zhiqiang Wu, Chuan Tong, Hanren Dai, Yelei Guo, Yang Liu, Jianhua Huang, Haiyan Lv, Can Luo, Kai-chao Feng, Qing-ming Yang, Xiao-lei Li, Weidong Han
Publikováno v:
OncoImmunology, Vol 7, Iss 7 (2018)
Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor sp
Externí odkaz:
https://doaj.org/article/f3e7c9850ad74bd1afb8b2aa4cd9e521
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Clinical response of primary-refractory HL in patients receiving CART-30 cell therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a173385b197c0426dadbd8612a367b5
https://doi.org/10.1158/1078-0432.22466207.v1
https://doi.org/10.1158/1078-0432.22466207.v1
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
The adverse event after the CART-30 cell infusion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a648396bc6857225f6946a93bc7a5919
https://doi.org/10.1158/1078-0432.22466213
https://doi.org/10.1158/1078-0432.22466213
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Case selection criteria;Methods;Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27ff9333a9cfe43c23835099d56866eb
https://doi.org/10.1158/1078-0432.22466222
https://doi.org/10.1158/1078-0432.22466222
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Lymphocyte recovery is a probable indictor of response.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d25c907ac14061cab2f18177a644ef9
https://doi.org/10.1158/1078-0432.22466216
https://doi.org/10.1158/1078-0432.22466216
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Maximum reduction in target lesion size.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e3d21148327eb22e8fbea1e3dbdea7
https://doi.org/10.1158/1078-0432.22466201
https://doi.org/10.1158/1078-0432.22466201
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Progression-free survival by Kaplan-Meier method.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a258997e6b7a0096c442f0096afcb779
https://doi.org/10.1158/1078-0432.22466210
https://doi.org/10.1158/1078-0432.22466210
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Purpose: Relapsed or refractory Hodgkin lymphoma is a challenge for medical oncologists because of poor overall survival. We aimed to assess the feasibility, safety, and efficacy of CD30-targeting CAR T cells in patients with progressive relapsed or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5344201df8fcf6ec36cfbe0d5c1e8163
https://doi.org/10.1158/1078-0432.c.6526262.v1
https://doi.org/10.1158/1078-0432.c.6526262.v1
Autor:
Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Supplementary Table S1. Phonotypical characteristics of PBMCs and expanded T Cells as well as transduction efficiency of infused cell products. Supplementary Table S2. Detailed prior chemotherapy regimens for patients before CD30-CART treatment. Supp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183c9e058c0c675172e2622a3f31586e
https://doi.org/10.1158/1078-0432.22466198.v1
https://doi.org/10.1158/1078-0432.22466198.v1